Designing a multipurpose technology for acceptability and adherence
•New MPTs must be efficacious, acceptable and effectively used to achieve a public health impact.•We identify three methods to examine users’ perceptions of and experiences with new products.•We describe how each method has informed decisions about contraceptive or HIV prevention products.•We sugges...
Gespeichert in:
Veröffentlicht in: | Antiviral research 2013-12, Vol.100, p.S54-S59 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •New MPTs must be efficacious, acceptable and effectively used to achieve a public health impact.•We identify three methods to examine users’ perceptions of and experiences with new products.•We describe how each method has informed decisions about contraceptive or HIV prevention products.•We suggest how these methods could inform development of new MPTs.
Multipurpose Prevention Technologies (MPTs) are new tools aimed at reducing or preventing multiple and overlapping sexual and reproductive health risks faced by women and couples around the globe. While MPTs could prove more acceptable and easier to adhere to than single-purpose prevention products, continuing high rates of HIV and unintended pregnancy remind us that these new products will need to be efficacious, acceptable and effectively used to achieve a public health impact. In this paper, we describe how a range of research methods can be applied during the pre-clinical phase of product development to inform decisions related to formulation and vehicle or product delivery mechanisms, and consider how choices in product-related characteristics may influence future demand for, delivery and use of future products. We draw on examples from the development of new single-purpose HIV and contraceptive products and then extend our discussion to the development of MPTs, including vaginal rings and injections. This article is based on a presentation at the “Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies,” held in Arlington, Virginia on February 21–22, 2013. It forms part of a special supplement to Antiviral Research. |
---|---|
ISSN: | 0166-3542 1872-9096 |
DOI: | 10.1016/j.antiviral.2013.09.029 |